



## Assertio Therapeutics and Purdue Pharma Settle Patent Infringement Lawsuit

August 28, 2018

### Purdue to pay Assertio \$62 million in two installments

LAKE FOREST, Ill., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that the Company has entered into a settlement agreement with Purdue Pharma L.P. with regard to the Company's patent infringement lawsuit against Purdue in the U.S. District Court for the District of New Jersey, in which the Company alleged infringement by Purdue of certain of the Company's patents in relation to Purdue's commercialization of Oxycontin® (oxycodone hydrochloride-controlled release).

Under the terms of the agreement, Purdue will pay Assertio a total of \$62 million in cash, with \$30 million in cash paid on August 28, 2018 and an additional \$32 million to be paid on February 1, 2019. The agreement resolves all pending claims between the two parties.

"We are extremely pleased to settle this litigation with Purdue in a manner that is favorable to the Company and to our shareholders," said Arthur Higgins, President and CEO of Assertio. "This infusion of cash, coupled with the \$20 million we recently received from our royalty sale to PDL BioPharma, further strengthens our balance sheet and improves our financial flexibility as we continue to transform the Company."

#### About Assertio Therapeutics, Inc.

Assertio Therapeutics is committed to providing responsible solutions to advance patient care in the Company's core areas of neurology, orphan and specialty medicines. Assertio currently markets three FDA-approved products and continues to identify, license and develop new products that offer enhanced options for patients that may be underserved by existing therapies. To learn more about Assertio, visit [www.assertiotx.com](http://www.assertiotx.com).

#### INVESTOR AND MEDIA CONTACT:

John B. Thomas  
SVP, Investor Relations and Corporate Communications  
[jthomas@assertiotx.com](mailto:jthomas@assertiotx.com)

 [Primary Logo](#)

Source: Assertio Therapeutics, Inc.